Search for more clinical trials
Leukemia Cell Cultures for Research of New Anti-Cancer Therapies
Conditions
Acute Leukaemia
Conditions: official terms
Leukemia
Conditions: Keywords
Leukaemia, Blood and marrow cells culture, Cell growth, Cell differentiation
Study Type
Interventional
Study Phase
N/A
Study Design
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Intervention
Name: Blood sampling
Type: Procedure
Name: Bone marrow aspiration
Type: Procedure
Overall Status
Recruiting
Summary
The main objective of this project is not only a better understanding of the human leukemic disease but also to find new anti-leukemic or improve existing ones. This study has, the following aims:
- To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences.
- To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts.
- To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.
- To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences.
- To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts.
- To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:
- Patients with suspected de novo or secondary or relapsed acute leukemia, requiring complementary blood test and bone marrow analysis
- Patients older or equal than 28 days
- Informed consent signed
Exclusion Criteria:
- Pregnancy
- Breastfeeding
- Patients with suspected de novo or secondary or relapsed acute leukemia, requiring complementary blood test and bone marrow analysis
- Patients older or equal than 28 days
- Informed consent signed
Exclusion Criteria:
- Pregnancy
- Breastfeeding
Locations
Service d'Hématologie et d'Oncologie
Strasbourg, France
Service de Pédiaterie - Hôpital de Hautepierre
Status: Recruiting
Contact: Raoul Herbrecht, MD - 3.33.88.12.83.79 - Raoul.herbrecht@chru-strasbourg.fr
Strasbourg, France
Status: Recruiting
Contact: Patrick Lutz, MD - 3.33.88.12.80.90 - Patrick.lutz@chru-strasbourg.fr
Start Date
July 2009
Sponsors
University Hospital, Strasbourg, France
Source
University Hospital, Strasbourg, France
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page